Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$2.53
+1.2%
$0.00
$1.07
$5.26
$91.49M0.8517,071 shs4,671 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$6.56
-7.1%
$0.00
$4.00
$9.86
$192.86M0.01324,656 shs327,591 shs
(COV) stock logo
COV
(COV)
$0.00
$65.97
$108.57
N/AN/A3.88 million shsN/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%0.00%+16.00%+49.43%-12.02%
(COV) stock logo
COV
(COV)
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
2.4721 of 5 stars
3.55.00.00.00.61.70.6
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
1.6261 of 5 stars
3.53.00.00.01.90.00.6
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
3.00
Buy$7.00176.59% Upside
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$25.72292.07% Upside
(COV) stock logo
COV
(COV)
N/AN/AN/AN/A

Current Analyst Ratings

Latest ARMP, ATNM, RAC, and COV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/1/2024
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$21.00
3/26/2024
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
3/22/2024
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
3/19/2024
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $30.00
3/19/2024
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$4.53M20.20N/AN/A($0.89) per share-2.84
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$80K2,410.80N/AN/A$1.31 per share5.01
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$69.04M-$1.98N/AN/AN/A-1,524.51%-280.95%-52.61%5/9/2024 (Estimated)
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.83N/A6.76N/AN/A-102.64%-52.57%5/15/2024 (Estimated)
(COV) stock logo
COV
(COV)
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest ARMP, ATNM, RAC, and COV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/29/2024Q4 2023
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$0.54-$0.33+$0.21-$0.33N/A$0.08 million
3/21/2024Q4 2023
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/A-$0.55-$0.55-$0.55$0.68 million$1.53 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/A
1.16
1.16
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
9.21
9.21
(COV) stock logo
COV
(COV)
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
3.57%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
(COV) stock logo
COV
(COV)
N/A

Insider Ownership

CompanyInsider Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
85.50%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
4.00%
(COV) stock logo
COV
(COV)
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
6636.15 million5.24 millionNot Optionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
4929.40 million28.22 millionNot Optionable
(COV) stock logo
COV
(COV)
N/AN/AN/ANot Optionable

ARMP, ATNM, RAC, and COV Headlines

SourceHeadline
Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscapeIdentifying efficacious SARS-CoV-2 antivirals in a changing immune landscape
thelancet.com - April 24 at 10:56 PM
Scientists report longest known ‘extreme’ Covid infection in 72-year-old manScientists report longest known ‘extreme’ Covid infection in 72-year-old man
yahoo.com - April 24 at 12:56 PM
Engineers muffle invading pathogens with a molecular maskEngineers muffle invading pathogens with a 'molecular mask'
msn.com - April 24 at 12:56 PM
COVID-19 virus disrupts protein production: Researcher discusses her recent findingsCOVID-19 virus disrupts protein production: Researcher discusses her recent findings
msn.com - April 24 at 12:56 PM
Reducing risks from respiratory pathogens at the 2024 HajjReducing risks from respiratory pathogens at the 2024 Hajj
thelancet.com - April 24 at 7:56 AM
WHO redefines airborne transmission: what does that mean for future pandemics?WHO redefines airborne transmission: what does that mean for future pandemics?
nature.com - April 24 at 7:56 AM
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutationsNew tARC-seq method enhances precision in tracking SARS-CoV-2 mutations
msn.com - April 24 at 7:56 AM
Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infectionsRepurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections
msn.com - April 24 at 2:54 AM
Influenza is considered the biggest pandemic threatInfluenza is considered the biggest pandemic threat
msn.com - April 24 at 2:54 AM
Global study reveals mismatch in COVID-19 treatment guidelines with WHO standardsGlobal study reveals mismatch in COVID-19 treatment guidelines with WHO standards
msn.com - April 24 at 2:54 AM
The truth about sudden deaths: no link to anti-Covid vaccinesThe truth about sudden deaths: no link to anti-Covid vaccines
thevermilion.com - April 23 at 9:53 PM
Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­upEx­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up
endpts.com - April 23 at 4:53 PM
Optimal timing maximizes Paxlovid benefits for treating COVID-19Optimal timing maximizes Paxlovid benefits for treating COVID-19
msn.com - April 23 at 4:53 PM
COVID Shot Boosts Mucosal Immunity in Previously Infected PeopleCOVID Shot Boosts Mucosal Immunity in Previously Infected People
medpagetoday.com - April 23 at 4:53 PM
How B cells recognize new variants of SARS-CoV-2How B cells recognize new variants of SARS-CoV-2
msn.com - April 23 at 4:53 PM
Optimal timing maximises Paxlovid benefits for treating COVID-19Optimal timing maximises Paxlovid benefits for treating COVID-19
elifesciences.org - April 23 at 8:56 AM
Does diabetes increase the risk of long COVID?Does diabetes increase the risk of long COVID?
msn.com - April 23 at 8:56 AM
How Ugandan Tobacco Farming Inadvertently Threatens Spread of Bat-Borne VirusesHow Ugandan Tobacco Farming Inadvertently Threatens Spread of Bat-Borne Viruses
scientificamerican.com - April 23 at 8:56 AM
Study discovers hidden mechanism behind rapid COVID variantsStudy discovers hidden mechanism behind rapid COVID variants
msn.com - April 23 at 8:56 AM
Man Utd: Neville makes ‘extreme’ Ten Hag sack claim; Carragher insists Cov display ‘cost’ him jobMan Utd: Neville makes ‘extreme’ Ten Hag sack claim; Carragher insists Cov display ‘cost’ him job
msn.com - April 22 at 3:31 PM
New technology uncovers mechanism affecting generation of new COVID variantsNew technology uncovers mechanism affecting generation of new COVID variants
msn.com - April 22 at 3:31 PM
Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre BioBoehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio
endpts.com - April 22 at 10:31 AM
COVID-19 vaccine-caused “turbo cancer” nonsense just keeps getting more turbocharged and nonsensicalCOVID-19 vaccine-caused “turbo cancer” nonsense just keeps getting more turbocharged and nonsensical
sciencebasedmedicine.org - April 22 at 10:31 AM
Advanced RNA Sequencing Reveals the Drivers of New COVID VariantsAdvanced RNA Sequencing Reveals the Drivers of New COVID Variants
scitechdaily.com - April 22 at 10:31 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Armata Pharmaceuticals logo

Armata Pharmaceuticals

NYSEAMERICAN:ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.
Actinium Pharmaceuticals logo

Actinium Pharmaceuticals

NYSEAMERICAN:ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
(COV) logo

(COV)

NYSE:COV
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.